Topic
Penicillium griseofulvum
About: Penicillium griseofulvum is a research topic. Over the lifetime, 169 publications have been published within this topic receiving 2702 citations.
Papers published on a yearly basis
Papers
More filters
TL;DR: This is the first record of P. griseofulvum on R. australe worldwide and symptoms appeared 8-10 days post inoculation on the leaves, from which the pathogen was reisolated, fulfilling Koch’s postulates.
Abstract: Rheum (Rheum australe, family Polygonaceae), a rhizomatous perennial herb with medicinal properties, is a rare and endangered species distributed in the Himalayas at an elevation of 2000- 4500 m above sea level (asl). In November 2011, a disease observed during domestication at Palampur, India (ca.1300 m asl), was characterized by irregular light-brown lesions on the leaves that gradually coalesced into larger blotches affecting the entire blade, which turned dark-brown and withered. Disease symptoms were oustanding during November–February, when the climate is cool (15-20°C) and were less prominent towards the end of March. A Penicillium sp. was consistently isolated when fragments from diseased leaves were surface-sterilised (2% sodium hypochlorite), and plated on potato dextrose agar (PDA). Colonies of single-spore isolates reached up to 8.0 cm diameter in 5 days at 28±2°C, were radially sulcate, often umbonate with usually deep margins, had terverticillate penicillia, with 4-7 phialides per verticil, bearing smooth-walled, ellipsoidal to subsphaeroidal conidia (Frisvad and Samson, 2004). The rDNA ITS was sequenced (GenBank accession No. KJ175262) and found identical (99%) to sequences of Penicillium griseofulvum isolates. Pathogenicity tests were done twice in a screenhouse by spraying a conidial suspension (1×106 conidia ml−1 in sterile tap water), obtained from 7-day-old cultures onto the healthy leaves of 10-month-old Rheum plants. Inoculated plants and water-sprayed controls were kept in a growth chamber at 20°C for 48-72 h. Symptoms appeared 8-10 days post inoculation on the leaves, from which the pathogen was reisolated, fulfilling Koch’s postulates. Control plants did not exhibit symptoms. P. griseofulvum has been reported as post-harvest pathogen (Spadaro et al., 2011). To our knowledge, this is the first record of P. griseofulvum on R. australe worldwide.
Patent•
16 Nov 2018
TL;DR: In this article, a griseofulvin-producing strain and application thereof were disclosed, and the Penicillium griseoenofulvum FH1816 provided by the invention is utilized to produce grISEOfulvin, a raw material route without using lactose and corn syrup and anew process of fed-batch fermentation with continuous feeding of chlorine are adopted, the fermentation potency of grise ofulvin can be greatly increased and the production cost can be reduced, and areliable raw material source was provided for development of the antifungal biop
Abstract: The invention discloses a griseofulvin-producing strain and application thereof. The invention provides Penicillium griseofulvum FH1816, which has a preservation number of CCTCC NO: M 2018187 in ChinaCenter for Type Culture Collection. The Penicillium griseofulvum FH1816 provided by the invention is utilized to produce griseofulvin, a raw material route without using lactose and corn syrup and anew process of fed-batch fermentation with continuous feeding of chlorine are adopted, the fermentation potency of griseofulvin can be greatly increased, and the production cost can be reduced, and areliable raw material source is provided for development of the antifungal biopesticide songgangmeisu.
Patent•
10 Sep 2019
TL;DR: In this paper, a preparation method of an anti-glioma active substance penicillium alkali ether A was proposed, which utilizes a marine strain of penicllium griseofulvum ZZ380.
Abstract: The invention provides a preparation method of an anti-glioma active substance penicillium alkali ether A, which utilizes a marine strain of penicillium griseofulvum ZZ380, cultures penicillium griseofulvum by utilizing a rice medium, greatly improves the yield of the anti-glioma active substance penicillium alkali ether A, and overcomes shortcomings of low yield of the penicillium alkali ether Aprepared by the prior art. The penicillium alkali ether A has significant inhibitory activity on human glioma cell proliferation, exhibits the characteristic of strong anti-glioma activity of the penicillium alkali ether A, and can be combined with a pharmaceutically acceptable carrier to form various dosage forms of drugs, and is used for treating glioma. Therefore, the penicillium alkali ether Ahas a good application prospect in preparation of anti-glioma drugs.
01 Jan 2016
TL;DR: In this article, the authors developed a high-throughput screening assay against Mycobacterium tu- berculosis (Mtb) PheRS and then screened a library consisting of 32,000 strains and 1500 natural product-derived compounds.
Abstract: 1 * Abstract: Phenylalanyl-tRNA synthetase (PheRS), a member of aminoacyl-tRNA syn- thetase family, was the new target of anti-tubercular drug discovery. In an attempt to fully exploit the new potential anti-tuberculosis drugs presented in micro-organ- isms, we developed a high-throughput screening assay against Mycobacterium tu- berculosis (Mtb) PheRS and then screened a library consisting of 32,000 strains and 1500 natural product-derived compounds. One potent hit extract of Penicillium gris- eofulvum CPCC-400528 was identified. In this study, isopatulin (1), (+)-epiepoformin (2) and gentisyl alcohol (3), three patulin-producing intermediates, together with three indole-tetramic acids, α-cyclopiazonic acid (4), β-cyclopiazonic acid (5) and iso-α-cyclopiazonic acid (6), were isolated and identified as bioactive constituents from P. griseofulvum CPCC-400528. Their structures were elucidated on the basis of spectroscopic data. Compounds 1, 3, 4, and 5 exhibited Mtb PheRS-inhibiting activi- ties, as well as moderate to weak anti-tuberculosis activities against Mtb H37Rv.